Demands For Extreme Diligence Will Be Balanced By Need For Deals
Executive Summary
A swing to excessive due diligence reviews by pharmaceutical companies will continue to be balanced by the urgency of acquiring late-stage products, Pharmacia VP-Licensing Thomas Picone, PhD, told a biotech meeting in late February